Recruiting

Testing a new immune cell therapy for rheumatoid arthritis

Plain-English translation of NCT06201416 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated July 2026 · How we translate trials

Read our Rheumatoid Arthritis research guide →

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing , a new type of treatment for rheumatoid arthritis that uses your own immune cells to help calm down inflammation in your joints. Researchers will give you a single dose or two smaller doses of these specially prepared cells through an IV infusion and monitor how safe the treatment is and how your body responds to it. The goal is to see if this medication can help reduce joint swelling and pain by helping your immune system restore balance.

Many people with rheumatoid arthritis don't respond well to current treatments or can't tolerate them. This trial exists to see if a new approach using your own immune cells might offer help to people whose arthritis hasn't improved with available options.

Do you qualify?

You likely qualify if…

you have been diagnosed with moderate-to-severe rheumatoid arthritis with active inflammation in your joints
you have tried at least two other types of rheumatoid arthritis medications without adequate benefit or could not tolerate them
you have at least four swollen joints and evidence of inflammation on clinical exam or ultrasound
you have kept your current rheumatoid arthritis medications at stable doses for at least 30 days
you have a BMI below 35 and are willing to use reliable birth control during the study

You likely don't qualify if…

you have had major surgery in the past 12 weeks or plan to have surgery within 12 months after receiving the treatment
you have an active infection or a history of recurring infections
you have untreated latent tuberculosis or active tuberculosis
you have a weakened immune system or primary immunodeficiency
you have uncontrolled heart, lung, kidney, liver, hormone-related, or digestive system disease

What participation looks like

You will receive either one intravenous infusion of the medication or two infusions spaced over time, depending on which group you're assigned to. The study involves safety monitoring, blood work, and assessments of your joint health and symptoms. As a Phase 1 trial, the focus is on understanding safety and how your body tolerates the treatment, so you can expect close follow-up appointments and regular check-ins with the research team.

AI-generated summary from trial data · Jul 1, 2026 · Not medical advice

Testing a new immune cell therapy for rheumatoid arthritis

What is this trial?

Do you qualify?

What participation looks like

Trial locations